Key facts
- This page summarizes Geraldine Henwood's Form 4 filing for Baudax Bio, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Dec 2022, 07:09.
Geraldine Henwood - 15 Dec 2022 Form 4 Insider Report for Baudax Bio, Inc.
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 15 Dec 2022
- Net transaction value
- +$3,057
- SEC form
- 4
- Accepted by SEC
- 19 Dec 2022, 07:09:42 UTC
- Prior SEC filing
- 17 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jillian Dilmore, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Geraldine Henwood filed Form 4 for Baudax Bio, Inc. on 19 Dec 2022.
Change
- Previous filing in this sequence was filed on 17 Jun 2022.
- Current net transaction value: +$3,057.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BXRX
transaction
Common Stock
Purchase
- Transaction value
- $3,057
- Shares
- +1,200
- Change %
- +98%
- Price
- $2.55
- Shares after
- 2,427
- Date
- 15 Dec 2022
- Ownership
- Direct
BXRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 14
- Date
- 15 Dec 2022
- Ownership
- By spouse
* marks a reported price that did not pass the local price check.